RYTM — Rhythm Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $6.06bn
- $5.83bn
- $189.76m
U.S. STOCKS ON THE MOVE-Boeing, Tesla, Icahn Enterprises
Rhythm Pharma rises as FDA grants priority review for genetic obesity drug
Brief: Rhythm Pharmaceuticals Announces FDA Acceptance For Priority Review Of Supplemental New Drug Application For Imcivree
Rhythm Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Rhythm Pharmaceuticals Q2 Net Income USD -32.263 Million
Rhythm Pharmaceuticals Inc expected to post a loss of 71 cents a share - Earnings Preview
Brief: Rhythm Pharmaceuticals Announces First Patients Dosed In Phase 2 Trial For Oral Mc4r Agonist Lb54640
Brief: Rhythm Pharmaceuticals Receives Positive CHMP Opinion For Imcivree For The Treatment Of Obesity And Control Of Hunger
Rhythm Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Rhythm Pharmaceuticals Q1 Net Income USD -141.372 Million
Rhythm Pharmaceuticals Inc expected to post a loss of $2.16 a share - Earnings Preview
Brief: Perceptive Advisors Reports 8.3% Stake In Rhythm Pharmaceuticals As Of April 15 Versus Previous Stake Of 5.4% As Of April 1- SEC Filing
Brief: Rhythm Pharmaceuticals Secures $150 Million In Convertible Preferred Stock Financing
Brief: Rhythm Pharmaceuticals Announces First Patient Dosed In Phase 1 Trial Evaluating RM-718
Brief: Perceptive Advisors Reports 5.4% Stake In Rhythm Pharmaceuticals- SEC Filing
Brief: Rhythm Pharmaceuticals Inc Files For Common Stock Offering Of Up To $200 Million- SEC Filing
Brief: Rhythm Pharmaceuticals Announces Clinical Development Plan Of Setmelanotide For Hypothalamic Obesity In Japan
Brief: Rhythm Pharmaceuticals Q4 Net Income USD -41.621 Million
Rhythm Pharmaceuticals Inc expected to post a loss of 70 cents a share - Earnings Preview